Assessment of Pain and Functional Recovery Following Anterior Cruciate Ligament Reconstruction Combined With Secretome Injection

Background Predictable graft healing following anterior cruciate ligament (ACL) reconstruction remains a clinical challenge, particularly because insufficient ligamentization and tendon–bone integration may be associated with graft failure and less favorable functional outcomes. Mesenchymal stem cell (MSC)-derived secretome represents a cell-free biological approach comprising diverse bioactive molecules with potential regenerative properties, as supported by preclinical studies. This study aimed to compare pain intensity and functional outcomes at six months after ACL reconstruction using a peroneus longus tendon (PLT) autograft, with and without adjunctive intralesional administration of MSC-derived secretome. Methods This study enrolled 24 patients undergoing arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction using a peroneus longus tendon (PLT) autograft. Participants were randomly allocated in a 1:1 ratio to receive either an intralesional injection of mesenchymal stem cell (MSC)-derived secretome into the graft (secretome group, n = 12) or an equivalent-volume saline placebo (control group, n = 12). Clinical outcomes were assessed preoperatively and at 6 months postoperatively using the International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form, Tegner–Lysholm Knee Scoring Scale, and Visual Analog Scale (VAS) for pain intensity. Between-group comparisons were conducted using the independent-samples t-test or Mann–Whitney U test, and followed by ANCOVA analysis as appropriate to the distributional characteristics of the data. Statistical significance was set at p < 0.05. Results At baseline, IKDC and VAS scores did not differ significantly between the secretome and control groups (IKDC: 48.57 ± 4.91 vs. 47.51 ± 4.45, p > 0.05; VAS: 7.75 ± 0.62 in both groups, p = 1.000). At the six months follow-up, patients receiving adjunctive secretome injection demonstrated significantly higher IKDC scores than controls (86.89 ± 5.11 vs. 78.27 ± 3.91, p < 0.01). Similarly, Tegner–Lysholm scores were significantly higher in the secretome group (87.08 ± 5.16 vs. 79.33 ± 2.67, p < 0.01). Pain intensity was also significantly lower in the secretome group, as reflected by lower VAS scores (2.17 ± 0.72 vs. 3.92 ± 0.79, p < 0.001). Conclusion Adjunctive MSC-derived secretome administration during anterior cruciate ligament (ACL) reconstruction using a peroneus longus tendon (PLT) autograft was associated with higher International Knee Documentation Committee (IKDC) subjective knee scores and Tegner–Lysholm knee scores, as well as lower Visual Analog Scale (VAS) pain scores, at 6 months postoperatively compared with saline placebo. These findings suggest the potential of MSC-derived secretome as a cell-free biological adjunct to improve patient-reported knee function and reduce postoperative pain following ACL reconstruction, warranting further evaluation in larger clinical trials.

Authors

Institutions

Publication Details

Journal
Orthopedic Reviews
Published
2026-11-16
DOI
https://doi.org/10.52965/001c.173764
Primary Topic
Knee injuries and reconstruction techniques
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Assessment of Pain and Functional Recovery Following Anterior Cruciate Ligament Reconstruction Combined With Secretome Injection

Febyan Febyan, Ni Made Puspa Dewi Astawa, I Wayan Subawa, Anak Agung Gde Yuda Asmara et al.
2 links
Orthopedic Reviews
Knee injuries and reconstruction techniques
article

Assessment of Pain and Functional Recovery Following Anterior Cruciate Ligament Reconstruction Combined With Secretome Injection

Febyan Febyan, Ni Made Puspa Dewi Astawa, I Wayan Subawa, Anak Agung Gde Yuda Asmara, I Ketut Suyasa, I Gusti Ngurah Wien Aryana
article en

Abstract

Background Predictable graft healing following anterior cruciate ligament (ACL) reconstruction remains a clinical challenge, particularly because insufficient ligamentization and tendon–bone integration may be associated with graft failure and less favorable functional outcomes. Mesenchymal stem cell (MSC)-derived secretome represents a cell-free biological approach comprising diverse bioactive molecules with potential regenerative properties, as supported by preclinical studies. This study aimed to compare pain intensity and functional outcomes at six months after ACL reconstruction using a peroneus longus tendon (PLT) autograft, with and without adjunctive intralesional administration of MSC-derived secretome. Methods This study enrolled 24 patients undergoing arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction using a peroneus longus tendon (PLT) autograft. Participants were randomly allocated in a 1:1 ratio to receive either an intralesional injection of mesenchymal stem cell (MSC)-derived secretome into the graft (secretome group, n = 12) or an equivalent-volume saline placebo (control group, n = 12). Clinical outcomes were assessed preoperatively and at 6 months postoperatively using the International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form, Tegner–Lysholm Knee Scoring Scale, and Visual Analog Scale (VAS) for pain intensity. Between-group comparisons were conducted using the independent-samples t-test or Mann–Whitney U test, and followed by ANCOVA analysis as appropriate to the distributional characteristics of the data. Statistical significance was set at p < 0.05. Results At baseline, IKDC and VAS scores did not differ significantly between the secretome and control groups (IKDC: 48.57 ± 4.91 vs. 47.51 ± 4.45, p > 0.05; VAS: 7.75 ± 0.62 in both groups, p = 1.000). At the six months follow-up, patients receiving adjunctive secretome injection demonstrated significantly higher IKDC scores than controls (86.89 ± 5.11 vs. 78.27 ± 3.91, p < 0.01). Similarly, Tegner–Lysholm scores were significantly higher in the secretome group (87.08 ± 5.16 vs. 79.33 ± 2.67, p < 0.01). Pain intensity was also significantly lower in the secretome group, as reflected by lower VAS scores (2.17 ± 0.72 vs. 3.92 ± 0.79, p < 0.001). Conclusion Adjunctive MSC-derived secretome administration during anterior cruciate ligament (ACL) reconstruction using a peroneus longus tendon (PLT) autograft was associated with higher International Knee Documentation Committee (IKDC) subjective knee scores and Tegner–Lysholm knee scores, as well as lower Visual Analog Scale (VAS) pain scores, at 6 months postoperatively compared with saline placebo. These findings suggest the potential of MSC-derived secretome as a cell-free biological adjunct to improve patient-reported knee function and reduce postoperative pain following ACL reconstruction, warranting further evaluation in larger clinical trials.

Orthopedic ReviewsVol. 18
Warmadewa University (ID)
Universitas Udayana
Good health and well-being
Knee injuries and reconstruction techniques
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon